

# Daniele Fanale

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1277796/publications.pdf>

Version: 2024-02-01

78  
papers

2,474  
citations

212478

28  
h-index

242451

47  
g-index

79  
all docs

79  
docs citations

79  
times ranked

4576  
citing authors

#	ARTICLE	IF	CITATIONS
1	Can the tumor-agnostic evaluation of MSI/MMR status be the common denominator for the immunotherapy treatment of patients with several solid tumors?. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 170, 103597.	2.0	19
2	BRCA1/2 variants of unknown significance in hereditary breast and ovarian cancer (HBOC) syndrome: Looking for the hidden meaning. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 172, 103626.	2.0	6
3	Impact of Different Selection Approaches for Identifying Lynch Syndrome-Related Colorectal Cancer Patients: Unity Is Strength. <i>Frontiers in Oncology</i> , 2022, 12, 827822.	1.3	6
4	MUTYH-associated tumor syndrome: The other face of MAP. <i>Oncogene</i> , 2022, 41, 2531-2539.	2.6	10
5	Immunometabolic predictive factors in Merkel cell carcinoma (MCC) patients treated with avelumab.. <i>Journal of Clinical Oncology</i> , 2022, 40, e21525-e21525.	0.8	2
6	Not all <i>KIT</i> 557/558 codons mutations have the same prognostic influence on recurrence-free survival: breaking the exon 11 mutations in gastrointestinal stromal tumors (GISTs). <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110497.	1.4	3
7	Type and Gene Location of KIT Mutations Predict Progression-Free Survival to First-Line Imatinib in Gastrointestinal Stromal Tumors: A Look into the Exon. <i>Cancers</i> , 2021, 13, 993.	1.7	14
8	Role of the HIPPO pathway as potential key player in the cross talk between oncology and cardiology. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 159, 103246.	2.0	3
9	Definition and management of colorectal polyposis not associated with APC/MUTYH germline pathogenic variants: AIFEG consensus statement. <i>Digestive and Liver Disease</i> , 2021, 53, 409-417.	0.4	9
10	Prognostic Role of Plasma PD-1, PD-L1, pan-BTN3As and BTN3A1 in Patients Affected by Metastatic Gastrointestinal Stromal Tumors: Can Immune Checkpoints Act as a Sentinel for Short-Term Survival?. <i>Cancers</i> , 2021, 13, 2118.	1.7	23
11	Prevalence and Spectrum of Germline BRCA1 and BRCA2 Variants of Uncertain Significance in Breast/Ovarian Cancer: Mysterious Signals From the Genome. <i>Frontiers in Oncology</i> , 2021, 11, 682445.	1.3	14
12	Challenges and advances for the treatment of renal cancer patients with brain metastases: From immunological background to upcoming clinical evidence on immune-checkpoint inhibitors. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 163, 103390.	2.0	10
13	POLE, POLD1, and NTHL1: the last but not the least hereditary cancer-predisposing genes. <i>Oncogene</i> , 2021, 40, 5893-5901.	2.6	34
14	Cancer of Exocrine Pancreas. <i>UNIPA Springer Series</i> , 2021, , 645-674.	0.1	0
15	Biomarkers. <i>UNIPA Springer Series</i> , 2021, , 43-64.	0.1	0
16	Tumor Board and Molecular Tumor Board. <i>UNIPA Springer Series</i> , 2021, , 401-409.	0.1	0
17	Tumor Biology and Natural History. <i>UNIPA Springer Series</i> , 2021, , 15-31.	0.1	0
18	Hereditary Cancers and Genetics. <i>UNIPA Springer Series</i> , 2021, , 65-98.	0.1	0

#	ARTICLE	IF	CITATIONS
19	Nutrition and Cancer. UNIPA Springer Series, 2021, , 381-389.	0.1	0
20	A "Lymphocyte MicroRNA Signature" as Predictive Biomarker of Immunotherapy Response and Plasma PD-1/PD-L1 Expression Levels in Patients with Metastatic Renal Cell Carcinoma: Pointing towards Epigenetic Reprogramming. Cancers, 2020, 12, 3396.	1.7	41
21	Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions. OncoImmunology, 2020, 9, 1832348.	2.1	55
22	Detection of Germline Mutations in a Cohort of 139 Patients with Bilateral Breast Cancer by Multi-Gene Panel Testing: Impact of Pathogenic Variants in Other Genes beyond BRCA1/2. Cancers, 2020, 12, 2415.	1.7	40
23	Hereditary Breast and Ovarian Cancer in Families from Southern Italy (Sicily)"Prevalence and Geographic Distribution of Pathogenic Variants in BRCA1/2 Genes. Cancers, 2020, 12, 1158.	1.7	30
24	<i>BRCA1/2</i> pathogenic variants in triple-negative <i>versus</i> luminal-like breast cancers: genotype"phenotype correlation in a cohort of 531 patients. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592097532.	1.4	34
25	Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC). Advances in Therapy, 2019, 36, 2600-2617.	1.3	80
26	Can the plasma PD-1 levels predict the presence and efficiency of tumor-infiltrating lymphocytes in patients with metastatic melanoma?. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591984887.	1.4	30
27	Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As, BTN3A1 and BTLA in patients with pancreatic adenocarcinoma. OncoImmunology, 2019, 8, e1561120.	2.1	92
28	Are Long Noncoding RNAs New Potential Biomarkers in Gastrointestinal Stromal Tumors (GISTs)? The Role of H19 and MALAT1. Journal of Oncology, 2019, 2019, 1-7.	0.6	13
29	Role of tumor-infiltrating lymphocytes in patients with solid tumors: Can a drop dig a stone?. Cellular Immunology, 2019, 343, 103753.	1.4	187
30	Effects of Dietary Restriction on Cancer Development and Progression. , 2019, , 1355-1373.		0
31	A novel predictive biomarker of immunotherapy response in metastatic renal cell carcinoma (mRCC): The lymphocyte microRNA expression profile.. Journal of Clinical Oncology, 2019, 37, e16109-e16109.	0.8	0
32	Monoclonal antibodies for the treatment of non-hematological tumors: a safety review. Expert Opinion on Drug Safety, 2018, 17, 1197-1209.	1.0	11
33	Circular RNA in Exosomes. Advances in Experimental Medicine and Biology, 2018, 1087, 109-117.	0.8	139
34	Spheroids from adipose"derived stem cells exhibit an miRNA profile of highly undifferentiated cells. Journal of Cellular Physiology, 2018, 233, 8778-8789.	2.0	20
35	Chloroquine plays a cell-dependent role in the response to treatment of pancreatic adenocarcinoma. Oncotarget, 2018, 9, 30837-30846.	0.8	18
36	Effects of Dietary Restriction on Cancer Development and Progression. , 2017, , 1-19.		1

#	ARTICLE	IF	CITATIONS
37	Cancer Clonal Evolution and Intra-tumor Heterogeneity. <i>Current Clinical Pathology</i> , 2017, , 27-39.	0.0	1
38	Target Therapies for Uterine Carcinosarcomas: Current Evidence and Future Perspectives. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1100.	1.8	29
39	Potential Role of ANGPTL4 in the Cross Talk between Metabolism and Cancer through PPAR Signaling Pathway. <i>PPAR Research</i> , 2017, 2017, 1-15.	1.1	119
40	The Interplay between Metabolism, PPAR Signaling Pathway, and Cancer. <i>PPAR Research</i> , 2017, 2017, 1-2.	1.1	55
41	Liquid Biopsy in Gastrointestinal Stromal Tumor. <i>Current Clinical Pathology</i> , 2017, , 151-159.	0.0	1
42	Analysis of miRNA expression profile induced by short term starvation in breast cancer cells treated with doxorubicin. <i>Oncotarget</i> , 2017, 8, 71924-71932.	0.8	26
43	Comment on: Survey of cervical cancer survivors regarding quality of life and sexual function. <i>Journal of Cancer Research and Therapeutics</i> , 2017, 13, 598-599.	0.3	7
44	Analysis of tissue and circulating microRNA expression during metaplastic transformation of the esophagus. <i>Oncotarget</i> , 2016, 7, 47821-47830.	0.8	36
45	Dietary restriction: could it be considered as speed bump on tumor progression road?. <i>Tumor Biology</i> , 2016, 37, 7109-7118.	0.8	24
46	Non-coding RNAs Functioning in Colorectal Cancer Stem Cells. <i>Advances in Experimental Medicine and Biology</i> , 2016, 937, 93-108.	0.8	24
47	The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet?. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 107, 20-32.	2.0	31
48	Involvement of Non-coding RNAs in Chemo- and Radioresistance of Colorectal Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2016, 937, 207-228.	0.8	55
49	A headlight on liquid biopsies: a challenging tool for breast cancer management. <i>Tumor Biology</i> , 2016, 37, 4263-4273.	0.8	18
50	Absence of germline CDKN2A mutation in Sicilian patients with familial malignant melanoma: Could it be a population-specific genetic signature?. <i>Cancer Biology and Therapy</i> , 2016, 17, 83-90.	1.5	18
51	HepatomiRNoma: The proposal of a new network of targets for diagnosis, prognosis and therapy in hepatocellular carcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 97, 312-321.	2.0	30
52	Triple negative breast cancer: shedding light onto the role of pi3k/akt/mTOR pathway. <i>Oncotarget</i> , 2016, 7, 60712-60722.	0.8	103
53	Can the microRNA expression profile help to identify novel targets for zoledronic acid in breast cancer?. <i>Oncotarget</i> , 2016, 7, 29321-29332.	0.8	23
54	Abstract 1855: Role of mTOR inhibition in triple-negative breast cancer. , 2016, , .		0

#	ARTICLE	IF	CITATIONS
55	Stabilizing versus Destabilizing the Microtubules: A Double-Edge Sword for an Effective Cancer Treatment Option?. <i>Analytical Cellular Pathology</i> , 2015, 2015, 1-19.	0.7	80
56	Prognostic and predictive biomarkers for targeted therapy in NSCLC: for whom the bell tolls?. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 1553-1566.	1.4	22
57	Targeted Therapies in Melanoma. <i>Current Clinical Pathology</i> , 2015, , 211-227.	0.0	4
58	New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?. <i>Oncotarget</i> , 2015, 6, 24780-24796.	0.8	77
59	Germline copy number variation in the <i>YTHDC2</i> gene: does it have a role in finding a novel potential molecular target involved in pancreatic adenocarcinoma susceptibility?. <i>Expert Opinion on Therapeutic Targets</i> , 2014, 18, 841-850.	1.5	44
60	The gene expression profile of cumulus cells reveals altered pathways in patients with endometriosis. <i>Journal of Assisted Reproduction and Genetics</i> , 2014, 31, 1277-1285.	1.2	10
61	Impact of microRNAs in Resistance to Chemotherapy and Novel Targeted Agents in Non-Small Cell Lung Cancer. <i>Current Pharmaceutical Biotechnology</i> , 2014, 15, 475-485.	0.9	54
62	Effects of PPAR $\alpha$ agonists on the expression of leptin and vascular endothelial growth factor in breast cancer cells. <i>Journal of Cellular Physiology</i> , 2013, 228, 1368-1374.	2.0	29
63	HIF-1 is involved in the negative regulation of AURKA expression in breast cancer cell lines under hypoxic conditions. <i>Breast Cancer Research and Treatment</i> , 2013, 140, 505-517.	1.1	29
64	Genetic and molecular characterization of the human Osteosarcoma 3AB $\alpha$ OS cancer stem cell line: A possible model for studying osteosarcoma origin and stemness. <i>Journal of Cellular Physiology</i> , 2013, 228, 1189-1201.	2.0	46
65	Effects of anti-miR-182 on TSP-1 expression in human colon cancer cells: there is a sense in antisense?. <i>Expert Opinion on Therapeutic Targets</i> , 2013, 17, 1249-1261.	1.5	41
66	Hypoxia and Human Genome Stability: Downregulation of BRCA2 Expression in Breast Cancer Cell Lines. <i>BioMed Research International</i> , 2013, 2013, 1-8.	0.9	32
67	Analysis of Germline Gene Copy Number Variants of Patients with Sporadic Pancreatic Adenocarcinoma Reveals Specific Variations. <i>Oncology</i> , 2013, 85, 306-311.	0.9	15
68	MicroRNAs in Colorectal Cancer Drug Resistance: Shooters become Targets. <i>Journal of Carcinogenesis &amp; Mutagenesis</i> , 2013, 04, .	0.3	3
69	MicroRNAs in colorectal cancer stem cells: new regulators of cancer stemness?. <i>Oncogenesis</i> , 2012, 1, e32-e32.	2.1	45
70	Analysis of molecular mechanisms and anti-tumoural effects of zoledronic acid in breast cancer cells. <i>Journal of Cellular and Molecular Medicine</i> , 2012, 16, 2186-2195.	1.6	23
71	Breast cancer genome-wide association studies: there is strength in numbers. <i>Oncogene</i> , 2012, 31, 2121-2128.	2.6	96
72	The role of microRNAs in cancer: diagnostic and prognostic biomarkers and targets of therapies. <i>Expert Opinion on Therapeutic Targets</i> , 2012, 16, S103-S109.	1.5	117

#	ARTICLE	IF	CITATIONS
73	Anti-endothelin drugs in solid tumors. Expert Opinion on Emerging Drugs, 2010, 15, 27-40.	1.0	16
74	R-Roscovitine (Seliciclib) prevents DNA damage-induced cyclin A1 upregulation and hinders non-homologous end-joining (NHEJ) DNA repair. Molecular Cancer, 2010, 9, 208.	7.9	13
75	Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?. Cancer Treatment Reviews, 2010, 36, S56-S61.	3.4	103
76	33 EFFECT OF miR-21, miR-182 AND let-7i ON TSP-1 EXPRESSION IN COLON CANCER CELL LINE. Cancer Treatment Reviews, 2010, 36, S104-S105.	3.4	1
77	43 CLINICAL SIGNIFICANCE OF INTRONIC VARIANTS OF BRCA GENES OF SICILIAN PATIENTS WITH HEREDITARY BREAST/OVARIAN CANCERS. Cancer Treatment Reviews, 2010, 36, S107-S108.	3.4	0
78	Is BRCA1-5083del19, identified in breast cancer patients of Sicilian origin, a Calabrian founder mutation?. Breast Cancer Research and Treatment, 2009, 113, 67-70.	1.1	23